ABBV vs BAC: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Bank of America Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Bank of America Corporation · Financial Services
$53.95
-41.2% upside to fair value
Grade C
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
BAC trades at a lower forward P/E
(12.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
BAC |
| Current Price |
$197.69 |
$53.95 |
| Fair Value Estimate |
$210.22 |
$31.74 |
| Upside to Fair Value |
+6.3%
|
-41.2%
|
| Market Cap |
$349.7B |
$387.2B |
| Forward P/E |
83.3x
|
12.3x
|
| EV / EBITDA |
23.4x
|
12.7x
|
| Price / Sales |
5.7x
|
2.2x
|
| Price / FCF |
18.7x
|
30.7x
|
| Revenue Growth YoY |
+10.0%
|
-35.6%
|
| Gross Margin |
70.2%
|
63.2%
|
| Operating Margin |
26.7%
|
22.9%
|
| Return on Equity |
-361.6%
|
10.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
3.26%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Bank of America Corporation is a leading diversified bank with $3.41 trillion in assets and a broad footprint across consumer banking, global markets, wealth management, and corporate banking. The company benefits from a strong market position and experienced leadership under CEO Brian T. Moynihan. However, the stock is currently overvalued, trading approximately 36% above its fair value estimate…
Accumulation Zones
| Metric |
ABBV |
BAC |
| Zone Low |
$157.66 |
$23.80 |
| Zone High |
$178.69 |
$26.98 |
| In Buy Zone? |
No
|
No
|